Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

Nintedanib is an intracellular inhibitor of tyrosine kinases used in the treatment of non–small cell lung cancer and idiopathic pulmonary fibrosis (IPF). This phase 1 open‐label study investigated the influence of mild and moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerab...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Pharmacol
Autors principals: Marzin, Kristell, Kretschmar, Gunther, Luedtke, Doreen, Kraemer, Sandrine, Kuelzer, Raimund, Schlenker‐Herceg, Rozsa, Schmid, Ulrike, Schnell, David, Dallinger, Claudia
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Special Populations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836871/
https://ncbi.nlm.nih.gov/pubmed/29106740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1025
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars